atlas-venture
(2)
Diagonal Therapeutics
Diagonal Therapeutics is a Watertown, Massachusetts biotech building 'clustering antibodies' - multi-specific, agonist antibodies that bind two or more cell-surface receptors at once to switch broken signaling pathways back on. Its DIAGONAL Product Engine combines computational and experimental screening to sift billions of antibody combinations for the rare ones that restore receptor activity. The lead program, DIAG723, restores dysregulated ALK1 signaling to address the root cause of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). Founded by Alex Lugovskoy with Atlas Venture, the company launched in 2024 with a $128M Series A and raised an oversubscribed $125M Series B in January 2026 to push DIAG723 into the clinic.
Vima Therapeutics
Vima Therapeutics is a Cambridge, Massachusetts clinical-stage biotechnology company developing VIM0423, a potential first-in-class once-daily oral therapy for isolated dystonia and Parkinson's disease. The drug selectively targets muscarinic cholinergic receptors in the brain to correct the dopamine-acetylcholine imbalance underlying these movement disorders. Incubated at Atlas Venture and led by neurologist Bernard Ravina, the company emerged from stealth in 2025 and has raised a $100 million Series A.